Severe gamma‐hydroxybutyrate withdrawal with delirium, hemodynamic lability, and rhabdomyolysis: A case series
The American Journal on Addictions · 2025
DOI: 10.1111/ajad.70013 ↗Kurz gefasst
Fallbericht in der Zeitschrift The American Journal on Addictions, 2025. Verfasst von Cara M Borelli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale University, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Delirium, Rhabdomyolysis, Sodium Oxybate, Substance Withdrawal Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Themen: Delir
Abstract (Originalsprache)
Background and Objectives Gamma‐hydroxybutyrate (GHB) use is clinically important in both the settings of overdose and withdrawal. GHB withdrawal varies in severity, and although mild cases can be managed outpatient, there are a range of presentations that include progression to severe withdrawal that require inpatient hospitalization.
Methods
We report a case series of two patients with severe GHB withdrawal who experienced complications of delirium, hemodynamic lability, and rhabdomyolysis and describe the treatment of these two cases of complex withdrawal.
Results
The first patient was successfully treated with a combination of a benzodiazepine taper and symptom‐triggered benzodiazepines with baclofen as an adjunct. The second patient had more severe symptoms and required intubation with a midazolam infusion, dexmedetomidine infusion, phenobarbital, baclofen, and a combination of a benzodiazepine taper and symptom‐triggered benzodiazepines. Discussion and Conclusions This case series highlights the potential complications of GHB withdrawal including delirium, hemodynamic lability, and rhabdomyolysis. Although rare in the United States, those working in addiction should have familiarity with the clinical course and complications of severe GHB withdrawal. Scientific Significance As one of the few detailed reports on severe GHB withdrawal and its potential complications, our findings extend the current body of literature by detailing the successful application of a multi‐modal treatment of severe GHB withdrawal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.
- Mount Sinai Hospital, Icahn School of Medicine, New York, New York, USA.
Zitieren
APA
Borelli, C. M., Kessler, N., Suter, D., & Levesque, A. (2025). Severe gamma‐hydroxybutyrate withdrawal with delirium, hemodynamic lability, and rhabdomyolysis: A case series. The American Journal on Addictions. https://doi.org/10.1111/ajad.70013
Vancouver
Borelli CM, Kessler N, Suter D, Levesque A. Severe gamma‐hydroxybutyrate withdrawal with delirium, hemodynamic lability, and rhabdomyolysis: A case series. The American Journal on Addictions. 2025. doi:10.1111/ajad.70013
BibTeX
@article{Borelli2025,
author = {Borelli, Cara M and Kessler, Newman and Suter, Daniel and Levesque, Annie},
title = {Severe gamma‐hydroxybutyrate withdrawal with delirium, hemodynamic lability, and rhabdomyolysis: A case series},
journal = {The American Journal on Addictions},
year = {2025},
doi = {10.1111/ajad.70013}
}
EUVIMED